BioCryst Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

• BioCryst Pharmaceuticals Inc BCRX.OQ reported quarterly adjusted earnings of 4 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -6 cents. The mean expectation of twelve analysts for the quarter was for earnings of one cent per share. Wall Street expected results to range from -1 cents to 10 cents per share.

• Revenue rose 49.4% to $163.35 million from a year ago; analysts expected $149.74 million.

• BioCryst Pharmaceuticals Inc's reported EPS for the quarter was 2 cents​.

• The company reported quarterly net income of $5.09 million.

• BioCryst Pharmaceuticals Inc shares had fallen by 11.3% this quarter and gained 5.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 10.8% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for BioCryst Pharmaceuticals Inc is $15.00, about 47% above its last closing price of $7.95

This summary was machine generated from LSEG data August 4 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)